ELISA Kit for Monocyte Chemotactic Protein 1 (MCP1)

15.6-1, 000pg/mL

The minimum detectable dose of this kit is typically less than 6.4pg/mL

3h

This assay has high sensitivity and excellent specificity for detection of Monocyte Chemotactic Protein 1 (MCP1).
No significant cross-reactivity or interference between Monocyte Chemotactic Protein 1 (MCP1) and analogues was observed.

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Monocyte Chemotactic Protein 1 (MCP1). Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated antibody specific to Monocyte Chemotactic Protein 1 (MCP1). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Monocyte Chemotactic Protein 1 (MCP1), biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Monocyte Chemotactic Protein 1 (MCP1) in the samples is then determined by comparing the O.D. of the samples to the standard curve.

Serum levels of selected chemokines in systemic lupus erythematosus patients; MRTF-A steers an epigenetic complex to activate endothelin-induced pro-inflammatory transcription in vascular smooth muscle cells; MicroRNA-155 Promotes Atherosclerosis Inflammation via Targeting SOCS1; НАРУШЕНИЕ БАЛАНСА ХРОМА И ВАНАДИЯ В ЖИРОВОЙ ТКАНИ КАК ВОЗМОЖНЫЙ МЕХАНИЗМ ОЖИРЕНИЕ-АССОЦИИРОВАННОЙ ИНСУЛИНОРЕЗИСТЕНТНОСТИ; Anti‐inflammatory properties of tianeptine on lipopolysaccharide‐induced changes in microglial cells involve toll‐like receptor‐related pathways; The serum concentrations of leptin and MCP-1 independently predict low back pain duration.; oxLDL antibody inhibits MCP‐1 release in monocytes/macrophages by regulating Ca2+/K+ channel flow; Metformin attenuates effects of cyclophilin A on macrophages, reduces lipid uptake and secretion of cytokines by repressing decreased AMPK activity; Increased Serum MCP-1 Levels in Systemic Vasculitis Patients with Renal Involvement; Long non-coding RNA mitigates atherosclerosis by regulating the actin-binding protein NEXN; A sensitive sandwich-type immunosensor for the detection of MCP-1 based on a rGO-TEPA-Thi-Au nanocomposite and novel RuPdPt trimetallic nanoalloy particles; Effect of stress hyperglycaemia on monocyte chemoattractant protein‑1 levels and the short‑term prognosis of patients with acute ST‑segment elevation myocardial …;